Lessening Organ Dysfunction With VITamin C - COVID-19
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
LOVIT-COVID is a multicentre concealed-allocation parallel-group blinded randomized
controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to
placebo on mortality or persistent organ dysfunction at 28 days in hospitalized COVID-19
patients.